Data published to the New England Journal of Medicine in late April showed Black and Latinx adults with moderate to severe asthma benefitted from the addition of a patient-directed, quick-reliever provisional inhaled glucocorticoid therapy along with their usual care.
0:16 The Discovery of Asthma
2:12 Introducing Elliot Israel, MD, and Juan Carlos Cardet, MD, MPH
3:20 Defining the SMART asthma strategy
5:46 The slow rollout of SMART
10:19 The strategy and findings of the PREPARE trial
21:41 How to initiate patient-activated reliever-triggered inhaled corticosteroid
25:15 The effect of COVID-19 on real-world asthma trials
27:40 How to lessen the disparities of asthma
The findings contribute to the prospect of implementing simpler care strategies for patients with difficult-to-control asthma, as well as feasible steps toward reducing asthma outcome disparities among people of color.
This May, during Asthma Awareness Month, the concept of PREPARE trial and its leading investigators headline a comprehensive discussion around mitigating key challenges in the chronic respiratory disease.
The newest episode of Lungcast features PREPARE investigators Elliot Israel, MD, of Harvard Medical School and Brigham and Women’s Hospital, and Juan Carlos Cardet, MD, MPH, of the University of South Florida Morsani College of Medicine.
Along with host Albert Rizzo, MD, chief medical officer of the American Lung Association (ALA), the research team discussed guideline-supported SMART strategy, the role of COVID in current asthma risks, and their own research into the disparate medical and financial impacts of asthma on the US patient population.
Lungcast is a monthly respiratory health podcast series from the ALA produced by HCPLive.
Subscribe or listen to Lungcast on your favorite platforms: